Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model.

CRV431 is a cyclophillin inhibitor. In addition to the UUO mouse model, this compound exerts its anti-fibrosis effects in other fibrosis models such as the STAM^TM mouse model, and is expected for future clinical development.

For detail information, see the Hepion pharma's press release.

http://irdirect.net/prviewer/release/id/4362811